Exhibit 99.1
NASDAQ : MBRX March 15, 2017
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward - looking statements . The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward looking statements . We have based these forward - looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short - term and long - term business operations and objectives, and financial needs . These forward - looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the “Risk Factors” section of the Form S - 1 filed with the SEC on February 7 , 2017 . Moreover, we operate in a very competitive and rapidly changing environment . New risks emerge from time to time . It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward - looking statements we may make . In light of these risks, uncertainties and assumptions, the future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements . More detailed information about Moleculin is set forth in our filings with the Securities and Exchange Commission . Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http : //www . sec . gov . 2
Recent Offering Issuer Moleculin Biotech, Inc. Security Unit consisting of one share of common stock and 1) an “A” five year w arrant to purchase 0.50 shares at $1.50 per share; 2) a “B” 90 day warrant to purchase 1.00 share of common stock at $1.35 per share; and 3) Upon exercise of the “B” warrant a “C” five year warrant to purchase 0.50 share at $1.50 per share NASDAQ Ticker MBRX Shares Outstanding After Completion of Offering 15,874,851 Units offered / Est. Net Proceeds 3,170,000 units / $4.4 million proceeds net of external and internal costs Price $1.35 per unit Use of Proceeds Preclinical and clinical development of drug pipeline Mgmt. Lock - Up Agreement 90 day lock - up Underwriter Roth Capital Partners and National Securities Corporation Closing Date February 14 , 2017 3
4 Robust pipeline 3 distinctly different technologies, all with blockbuster potential World - leading collaboration MD Anderson Cancer Center Breakthrough disruptive technologies Annamycin for AML: little to no cardiotoxicity , avoids MDR1 WP1066: STAT3 inhibitor that also stimulates immune response WP1122: metabolic inhibitor with improved BBB transmission Highly experienced leadership Veteran pharma/biotech, life science micro - cap managers Proprietary positioning Orphan drug (applied) and/or patents, exclusive licenses
Experienced Management Team Selected Prior Experience Walter Klemp Chairman & CEO Don Picker, PhD President & COO Jonathan P. Foster. CPA, CGMA EVP & CFO Robert Shepard, MD, FACP Chief Medical Officer 5 #1
Selected Prior Experiene Waldemar Priebe, PhD Madeleine Duvic, MD John Paul Waymack, MD, SCD Sandra Silberman, MD, PhD Science Advisory Board Members 6
Development Pipeline 7 Discovery (Finding potential new drugs) Pre - Clinical Development (Laboratory Testing) IND Filing (Investigational New Drug; FDA Filing) Phase I/II (Human safety & proof of concept) Approval Trial (Phase IIb or III as required) Adult AML WP1066 (Glioblastoma, metastatic melanoma) WP1122 (Glioblastoma) CNS malignancies Pediatric acute leukemia WP1220 (CTCL) Diagnostics WP1066 (Pancreatic, other) Annamycin WP1066 Portfolio WP1122 Portfolio Sponsored Research = Potential key value inflection point
Value Inflection Points Points we consider to be key development milestones that may influence big pharma’s decision to license or acquire: • Annamycin – generation of Phase I/II data consistent with the clinical trials already completed • WP1066 and WP1122 – Proof of concept (showing activity against the targeted indication) in planned Phase I/II trials We believe we have the potential to hit one or more of these value inflection points within 2 - 3 years 8
Development Strategy 9 • Orphan Drug targets with high revenue potential • Focus on game - changing breakthroughs • Collaborate closely with MD Anderson Cancer Center • Minimize cash burn through virtual structure • Worldwide exclusive licenses and regulatory exclusivity create proprietary positioning for all projects
Industry Opportunity 10 • Orphan Drug sales represented approximately $29 billion in revenue in 2013 • There are no approved second - line therapies for AML • CPXX sold for $1.5 billion based on improving OS by 3.5 months, yet still leaves most AML patients without hope • Similar opportunities exist in brain tumors, pancreatic cancer and other rare diseases we are pursuing
Most of our technologies were developed at MD Anderson Cancer Center, the world’s largest cancer research facility centered within the world’s largest medical center With over 1 , 500 cancer researchers, our sponsored research has been supported by truly state of the art resources 11
Delivering Solutions 12
Annamycin Critical Advantages over Leading Drug Leading drugs are cardiotoxic and lose efficacy due to multidrug resistance Annamycin has shown little to no cardiotoxicity , avoids multidrug resistance, has been shown to be more potent in AML cell lines and has shown activity in patients who failed standard of care Potential to Significantly Improve Health Annamycin has shown the potential to significantly improve health in a Phase I/II acute myeloid leukemia (AML) trial Potential for Orphan Drug status as single agent for relapsed or refractory AML Positioned for Accelerated Approval Annamycin appears to be well suited for an accelerated approval pathway here in the US, and in Europe Absence of any approved second - line drug represents a significant unmet need Potentially shorter time scale for saving lives than with typical cancer drugs 13 Annamycin Process
14
Annamycin Delivers Remarkable Performance In a proof - of - concept Phase I/II clinical trial, Annamycin was given to patients who had failed an average of five previous induction therapy attempts 37% of those patients cleared enough of their leukemic cells to qualify for a bone marrow transplant We believe repeating this performance in a larger clinical trial, could warrant new drug approval However, we believe MTD was understated in this trial, giving us an opportunity to do even better Relapsed/Refractory Acute Leukemia Patients 63% Efficacy Signal 37% Cleared Bone Marrow Blasts Annamycin gives new hope to patients who have run out of options 15 Relapsed/Refractory Acute Leukemia Patients
20% 80% Induction Therapy (Qualify for BMT) Success Failure 80 % 20 % BMT (Results in Cure) Leukemia is a cancer of the white blood cells and the acute forms of leukemia can manifest quickly and leave patients with limited treatment options The only viable option for acute leukemia patients is a bone marrow transplant (BMT), and those BMTs are successful about 80% of the time The problem is that in order to qualify for a BMT, patients have to first eliminate most of their cancerous white blood cells through what is called “induction therapy” However, induction therapy is currently only successful in about 20% of patients Annamycin has the potential to qualify more people for induction therapy 16
17 Annamycin (based on last trial) What is possible if we get to patients sooner with a higher MTD?
WP1066 Portfolio Overview Based On Natural Compound Built from chemical backbone of bee pollen compound Unique Dual Action First drug to both directly inhibit tumor signaling while also stimulating patient immune response Activity Against Hardest - to - Treat Cancers Pre - clinical testing shows high level of activity against pancreatic cancer, metastatic melanoma, glioblastoma and others; yet very low potential for toxicity Independently Validated Subject of numerous peer reviewed journals validating findings across multiple institutions around the world 18 WP1066 Process
Proposed MOA of WP1066: Deubiquitinase - Mediated Control of p - STAT3 19 Proteasome Proteasomal Degradation p - STAT3, an activated form of STAT3 Ubiquitinated STAT3 Activated STAT3 (p - STAT3) relies on deubiquitinating enzymes (DUBs) to reverse ubiquitination and decrease proteasomal hydrolysis WP1066 inhibition of DUBs increases ubiquitination of p - STAT3 and leads to the depletion of this oncogenic protein in the tumor cell WP1066 blockade Aberrant deubiquitination can lead to constitutive activation of STAT3 WP1066 blocking of DUBs shifts the equilibrium towards ubiquitinated p - STAT3
WP1122 Portfolio Overview Tumor cell Normal cell Addicted to Sugar A brain tumor requires as much as 18 to 37 times as much glucose to survive as a healthy brain cell Starving a Tumor to Death This eventually led to the theory that, if we feed tumor cells a glucose decoy (one that can’t convert into energy), we can kill the tumor This works well in a laboratory setting, but the problem is making these decoys drugable Breakthrough design WP1122 has been combined with a pro - drug to increase half - life and enable transmission across the blood brain barrier Potential to Change Standard of Care WP1122 (at suboptimal doses) performs as well or better than temozolomide in live human brain tumors; even better performance by combining the two drugs was shown in trials 20 Tumors are hyper - consumers of glucose and starve to death without it
WP1122 is Effective In Vivo against Gliomas 21 Orthotopic Glioblastoma Model in Mice WP1122 used alone has at least the same or greater activity than temozolomide ( Temodar ® ), a current standard of care in patients diagnosed with glioblastoma 0 2 4 6 8 10 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 # of Animals Days Control Temodar WP1122
Financial Overview 22
Financial Statement Summary The above unaudited financial information should be read with the notes, the financial statements of Moleculin and the notes the reto which are included in the Form 10 - Q for the quarter ended September 30, 2016 . 23 For the Nine Months Ended September 30, 2016 From July 29, 2015 (Inception) to September 30, 2015 (Unaudited) (Unaudited) Statement of Operations Data - MBI Revenue $ - $ - Research and development expense 616,498 38,409 General and administrative expense 1,849,242 184,344 Other expense 37,307 1,562 Net loss ($2,503,047) ($224,315) Net loss per common share ($0.28) ($0.05) September 30, 2016 (Unaudited) Balance Sheet Data - MBI Cash and cash equivalents $6,183,783 Working capital deficit 5,148,499 Total assets 17,573,788 Accumulated deficit (3,251,407) Total stockholders’ equity 16,243,635
Upcoming Potential Milestones Annamycin • Approval of an Investigative New Drug application by the FDA (first half of 2017) • Receipt of Orphan Drug Status (first half of 2017) • Announcement of the beginning of Phase I/II clinical trials (first half of 2017) • Establishment of the MTD (2017) • Results of the Phase I/II trial (2018) W1066 • Approval of a physician sponsored Investigative New Drug application by the FDA (2017) • Benefits of Sponsored Research Agreements with MD Anderson (2017 - 2018)
25 Robust pipeline 3 distinctly different technologies, all with blockbuster potential World - leading collaboration MD Anderson Cancer Center Breakthrough disruptive technologies Annamycin for AML: little to no carditoxicity , avoids MDR1 WP1066: STAT3 inhibitor that also stimulates immune response WP1122: metabolic inhibitor with improved BBB transmission Highly experienced leadership Veteran pharma/biotech, life science micro - cap managers Proprietary positioning Orphan drug (applied) and/or patents, exclusive licenses
